Clinical trials have demonstrated the efficacy of Opdivo in improving overall survival and progression-free survival for several types of cancer. For example, in melanoma, Opdivo has shown significant benefits in both first-line and previously treated patients. In NSCLC, it has been effective in patients with and without prior chemotherapy. The clinical outcomes vary by cancer type and individual patient factors.